1. Home
  2. QNC vs DMAC Comparison

QNC vs DMAC Comparison

Compare QNC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QNC

Quantum eMotion Corp. Common Shares

N/A

Current Price

$2.22

Market Cap

434.7M

Sector

N/A

ML Signal

N/A

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$6.57

Market Cap

363.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNC
DMAC
Founded
2007
2000
Country
Canada
United States
Employees
5
35
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.7M
363.7M
IPO Year
2026
2018

Fundamental Metrics

Financial Performance
Metric
QNC
DMAC
Price
$2.22
$6.57
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
621.4K
157.4K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$4.63
52 Week High
$3.59
$10.42

Technical Indicators

Market Signals
Indicator
QNC
DMAC
Relative Strength Index (RSI) 44.07 45.66
Support Level $1.91 $6.25
Resistance Level $2.31 $7.28
Average True Range (ATR) 0.13 0.31
MACD 0.04 -0.03
Stochastic Oscillator 78.05 38.15

Price Performance

Historical Comparison
QNC
DMAC

About QNC Quantum eMotion Corp. Common Shares

Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: